<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191162</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003789-21</org_study_id>
    <nct_id>NCT03191162</nct_id>
  </id_info>
  <brief_title>Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.</brief_title>
  <acronym>MULTIBENZ</acronym>
  <official_title>Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 clinical trial to evaluate the the efficacy of different benznidazole regimens
      (300mg/day for 60 days, 150mg/day for 60 days, and 400mg/day for 15 days) for the treatment
      of chronic Chagas disease in adult patients. The efficacy is assessed through the proportion
      of patients with negative parasitaemia measured by Polymerase Chain Reaction (PCR) during the
      first 12 months after starting treatment. The study will be performed in Spain, Brazil,
      Argentina and Colombia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatment</measure>
    <time_frame>12 months</time_frame>
    <description>The treatment efficacy is assessed through the proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chagas Disease</condition>
  <condition>Trypanosoma Cruzi Infection</condition>
  <arm_group>
    <arm_group_label>B300/60</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benznidazole 300mg/day p.o. divided in two doses for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B150/60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benznidazole 150mg/day p.o. divided in two doses for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B400/15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benznidazole 400mg/day p.o. divided in two doses for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease</description>
    <arm_group_label>B300/60</arm_group_label>
    <arm_group_label>B150/60</arm_group_label>
    <arm_group_label>B400/15</arm_group_label>
    <other_name>Abarax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years old.

          -  Diagnosis of Chagas disease through two different serological tests.

          -  Positive T. cruzi PCR in peripheral blood.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Previous treatment with Benznidazole or Nifurtimox.

          -  Alcohol consumption.

          -  Acute or chronic health problems that could interfere in the assessment of the
             efficacy or safety of the drug (acute infections, HIV infection, liver or renal
             impairment, etc).

          -  Nitroimidazole hipersensitivity.

          -  Concomitant or previous treatment with allopurinol or antifungal drugs.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israel Molina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Vall d'Hebron Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Israel Molina, PhD</last_name>
    <phone>0034 93 274 6251</phone>
    <email>imolina@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Salvador, MD</last_name>
    <phone>0034 93 274 6251</phone>
    <email>fmsalvad@vhebron.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Parasitología Dr. Mario Fatala Chaben (ANLIS)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marisa Fernández</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiología de Corrientes Juana Francisca Cabral</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria del Carmen Bangher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas René Rachou - Fundação Oswaldo Cruz. (FIOCRUZ)</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo Correa Oliveira</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Clemente de Faria</name>
      <address>
        <city>Montes Claros</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Luiz Pinho Ribeiro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Cardioinfantil - Instituto de Cardiología</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Carlos Villar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Atencion y Diagnóstico de Enfermedades Infecciosas</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa Marina Rojas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Department Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molina Israel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Molina Israel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benznidazole</keyword>
  <keyword>PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

